**General Policy**

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research programmes of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

**Editorial Office**

Manuscripts and correspondence should be addressed to: Dr. J.G. Delinassios, Managing Editor, IN VIVO Editorial Office, International Institute of Anticancer Research, 1st km Kapandriotou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR website: www.iiar-anticancer.org

**Selection of Recent Articles**

Small Molecule GS-Nitroxide Ameliorates Ionizing Irradiation-Induced Delay in Bone Wound Healing in a Novel Murine Model. A. GORHAELE, J.-C. RWIGEMA, M. EPPERLY, J. GLOWACKI, H. WANG, J.GOFF, T. DIXON, K. PATRENE, J.S. GREENBERGER (Pittsburgh, PA; Boston, MA, USA)


Effects of Voluntarily Ingested Buprenorphine on Plasma Corticosterone Levels, Body Weight, Water Intake, and Behaviour in Permanently Catheterised Rats. R. GOLDRUHL, J. HAU, K.S.P. ABELSON (Uppsala, Sweden; Copenhagen, Denmark)

Pharmacologic Ascorbic Acid Suppresses Syngeneic Tumor Growth and Metastases in Hormone-Refractory Prostate Cancer. H.B. POLLARD, M.A. LEVINE, O. EIDELMAN, M. POLLARD (Bethesda, MD; Notre Dame, IN, USA)


Modulation of Aged Murine T Lymphocytes In Vivo by DPV576-C, a Nanodiamond- and Nanoplatinum-coated Material. M. GHONEUM, L. TOLENTINO, J. GIMZEWSKI (Los Angeles, CA, USA)


Effects of Fetal Exposure to 4-n-octylphenol on Mammary Tumorigenesis in Rats. H. KAWAGUCHI, N. MIYOSHI, Y. MIYAMOTO, M. SOUDA, Y. UMEKITA, N. YASUDA, H. YOSHIDA (Kagoshima, Japan)

Comparative Study of Difference Between Long and Short Pulse on Treating Melanoma In Vivo. X. CHEN, R.J. SWANSON, K.H. SCHÖNBACH, S. ZHENG (Zhejiang, China; Norfolk, VA, USA)

Tetrandrine Pre-Treatment has Protective Effects Against Isoproterenol-induced Myocardial Infarction in Rabbits. A. PINELLI, S. TRIVULZIO, S. BRENNA, G. ROSSONI (Milan, Italy)

Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDEG, K.-M. MYHR, H.I. YLAND (Bergen, Norway)

Development of IMR Tests for Children with Central Auditory Processing Disorders. S. BARTEL-FRIEDRICH, Y. BROCCKER, M. KNOERGEN, S. KAESLING (Halle/Saale, Germany)


**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**
Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios  
   International Institute of Anticancer Research (IIAR)  
   Editorial Office of ANTICANCER RESEARCH,  
   IN VIVO, CANCER GENOMICS and PROTEOMICS.  
   1st km Kapandritiou-Kalamou Road  
   P.O. Box 22, GR-19014 Kapandriti, Attiki  
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Papers

Epigenetic Inactivation of the Placentally Imprinted Tumor Suppressor Gene TFPI2 in Prostate Carcinoma. T. RIBARSKA, M. INGEN-WERTH, W. GOERING, R. ENGERS, W.A. SCHULZ (Düsseldorf, Germany)

Cancer-related Issues of CD147. U.H. WEIDLE, W. SCHEUER, D. EGGLE, S. KLOSTERMANN, H. STOCKINGER (Penzburg, Germany; Vienna, Austria)

Spontaneous In Vitro Transformation of Primary Human Osteoblast-like Cells. U. MAGDOLEN, M. SCHMITT, B. HILDEBRANDT, P. DIEHL, J. SCHAUWECKER, B. SALDAMLI, R. BURGKART, J. TÜBEL, R. GRADINGER, B. ROYER-POKORA (Muenchen; Düsseldorf; Rostock, Germany)

Inhibition of c-Jun N-terminal Kinase (JNK) by SP600125 : A cDNA Microarray Analysis. P. CHAMPELOVIER, M. EL ATIFI-BOREL, J.P. ISSARTEL, J. BOUTONNAT, F. BERGER, D. SEIGNEURIN (Grenoble, France)

Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in Human Breast Cancer, Expression Pattern and Clinical/Prognostic Relevance. S. CHENG, A. DOUGLAS-JONES, X. YANG, R.E. MANSEL, W.G. JIANG (Cardiff, UK; Beijing, China)

Metalloproteome of the Prostate: Carcinoma Cell Line DU-145 in Comparison to Healthy Rat Tissue. J. BARTEL, J. BARTEL, D. SCHMIDT, I. GRBAVAC, A. KYRIAKOPOULOS (Berlin, Germany)

Identification of Serpin (α-1-antitrypsin) as Serum Growth Inhibitory Factor in Murine Ehrlich Carcinoma by Proteomics. F.V. DONENKO, R.K. ZIGANSHIN, N.Y. ANISIMOVA, K.E. VOYUSHIN, S.M. SITDIKOVA, B.S. AMANDZHOLOV, M.V. KISELEVSKII, T. EFFERTH (Moscow, Russia; Mainz, Germany)

DNA-Based Assay for EPB6 Expression in Breast Carcinoma Cells as a Potential Diagnostic Test for Detecting Tumor Cells in Circulation. B.P. FOX, R.P. KANDPAL (Pomona, CA, USA)

Molecular Profiling Using Tissue Microarrays as a Tool to Identify Predictive Biomarkers in Laryngeal Cancer Treated with Radiotherapy. G. HOLGERSSON, S. EKMAN, J. REIZENSTEIN, M. BERGQVIST, F. PONTÉN, M. UHLÉN, K. MAGNUSSON, P. JONNALAGADDA, A. ASPLUND, S. STRÖMBERG, A. LINDE, E. BLOMQVIST, M. LILJEHOLM, B. LÖDÉN, K. HELLSTRÖM, S. BERGSTRÖM (Uppsala; Örebro; Gävle; Karlstad, Sweden; Mumbai, India)
Phase II Trial of Adjuvant Chemotherapy with Bi-Weekly Carboplatin Plus Paclitaxel in Patients with Completely Resected Non-small Cell Lung Cancer. M. Sugaya, H. Uramoto, A. Uchiyama, A. Nagashima, R. Nakanishi, H. Sakata, K. Nakanishi, T. Hanagiri, K. Yasumoto (Kitakyushu; Kyushu Kouseinenkin; Iizuka City, Japan) ................................................................. 3039

Hepatic Arterial Infusion with Oxaliplatin, Irinotecan and Doxifluridine for Unresectable Liver Metastases of Colorectal Cancer. Y. Chen, Z. Yan, J. Wang, X. Wang, J. Luo, Q. Liu (Shanghai, China) ........ 3045

Trastuzumab plus Capecitabine and Docetaxel as First-line Therapy for HER2-positive Metastatic Breast Cancer: Phase II Results. V. Michalaki, S. Fotiou, S. Gennatas, C. Gennatas (Athens, Greece) ............. 3051

Stereotactic Radiosurgery plus Whole-brain Radiotherapy for Treatment of Multiple Metastases from Non-small Cell Lung Cancer. G. Minniti, M. Salvati, R. Muni, G. Lanzetta, M.F. Osti, E. Clarke, A. Costa, A. Bozzao, G. Trasimeni, R. Maurizi Enrici (Rome; Pozzilli (IS), Italy) .............. 3055


Does a New Ultrasound Probe Change the Complication Rates of Transrectal Ultrasound-guided Needle Biopsies of the Prostate? T.H. Ecke, H. Gerullis, C.J. Heuck, P. Bartel, S. Hallmann, S. Koch, J. Ruttloff (Bad Saarow; Neuss; Essen, Germany; Bronx, NY, USA) ................................ 3071

Preliminary Results of Tranilast Treatment for Patients with Advanced Castration-resistant Prostate Cancer. K. Izumi, A. Mizokami, T. Shima, K. Narimoto, K. Sugimoto, Y. Kobori, Y. Maeda, H. Konaka, E. Koh, M. Namiki (Kanazawa; Koshigaya, Japan) .......................................................... 3077

Fine-Needle Aspiration Cytology and $^{99m}$Tc-pertechnetate Scintigraphy Together in Patients with Differentiated Thyroid Carcinoma. F. Lumachi, M. Fabbro, A. Tregnaghi, L. Antunovic, F. Bui, D. Cecchini, P. Zucchetta, A. Fassina (Padova, Italy) ................................................................. 3083


Prognostic Significance of Tumour Marker Index Based on Preoperative CEA and CYFRA 21-1 in Non-small Cell Lung Cancer. M. Tomita, T. Shimizu, T. Ayabe, A. Yoney, T. Onitsuka (Miyazaki, Japan) .................................................................................................................................................. 3099

* Review (page 2943)
Postoperative External Beam Radiotherapy for Resected Pancreatic Adenocarcinoma: Impact of Chemotherapy on Local Control and Survival. K. OGAWA, H. SHIBUYA, N. UCHIDA, H. ONISHI, Y. OKUNO, M. MYOJIN, M. KOBAYASHI, Y. OGAWA, N. KANESAKA, K. SHIBUYA, S. TOKUMARU, R. SASAMOTO, K. KARASAWA, K. NEMOTO, Y. NISHIMURA, JROSG WORKING SUBGROUP of GASTROINTESTINAL CANCER (Okinawa; Tokyo; Shimane; Yamanashi; Kobe City; Sapporo; Sendai; Kyoto; Saga; Niigata; Yamagata; Osaka, Japan) ................................................................. 2959


Prognostic Value of Lymphovascular Invasion in Bladder Cancer in Patients Treated with Radical Cystectomy. F. PALMIERI, E. BRUNOCILLA, A. BERTACCINI, M. GUIDI, R. PERNETTI, A.M. MORSELLI-LABATE, G. MARTORANA (Bologna, Italy) ................................................................. 2973

Influence on Busilvex® Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data. E. CARRERAS, J.Y. CAHN, C. PUOZZO, N. KRÖGER, G. SANZ, A. BUZYN, A. BACIGALUPO, J.P. VERNANT (Barcelona; Valencia, Spain; Grenoble; Toulouse; Paris, France; Hamburg, Germany; Genova, Italy) .. 2977

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. N. YAMAMOTO, T. YAMANAKA, Y. ICHINOSE, K. KUBOTA, H. SAKAI, A. GEMMA, N. SAJO, M. FUKUOKA, H. NITANI (Shizuoka; Fukuoka; Tokyo; Saitama; Osaka, Japan) ................................................................. 2985

Cervical Manifestation of a Borderline Type Ovarian Cancer with Pseudomyxoma Peritonei – A Case Report. R.B. SCHMUCK, K. PIETZNER, A. BUCKENDAHLE, J. SCHÖNLEBE, J. SEHOULE (Berlin; Dresden, Germany) ................................................................. 2991

Immunohistochemical Study of Claudin 18 Involvement in Intestinal Differentiation During the Progression of Intraductal Papillary Mucinous Neoplasm. Y. SANADA, Y. HIROSE, S. OSADA, Y. TANAKA, T. TAKAHASHI, K. YAMAGUCHI, K. YOSHIDA (Gifu, Japan) ................................................................. 2995

Successful Right Hepatectomy After Four Treatments of Yttrium-90 Microspheres (SIR-Spheres®) and Concomitant FOLFOX as Bridging Therapy to Resection of Colorectal Liver Metastases. T.C. CHUA, L. BESTER, J. AKTHER, D.L. MORRIS (Sydney, Australia) ................................................................. 3005

Amyloid Deposition in the Tongue: Clinical and Histopathological Profile. F. ANGIERO, R. SERAMONDI, S. MAGISTRO, R. Crippa, S. BENEDICENTI, C. RIZZARDI, G. CATTORETTI (Monza; Milan; Genoa; Trieste, Italy) ................................................................. 3009


Protruding and Non-protruding Colon Carcinomas Originating in Gut-associated Lymphoid Tissue. C.A. RUBIO, C. LINDH, J. BJÖRK, H. TÖRNBLOM, R. BEFRITS (Stockholm, Sweden) ................................................................. 3019


Contents continued on the preceding page
y-Tocotrienol Controls Proliferation, Modulates Expression of Cell Cycle Regulatory Proteins and Up-regulates Quinone Reductase NQO2 in MCF-7 Breast Cancer Cells. T.C. HSIEH, S. ELANGOVAN, J.M. WU (Valhalla, NY, USA) ......................................................... 2869


Induction of Apoptosis by Sphingosine, Sphinganine, and C2-Ceramide in Human Colon Cancer Cells, but not by C2-Dihydroceramide. E.H. AHN, J.J. SCHROEDER (Gyeonggi-do, South Korea; East Lansing, MI, USA) ......................................................... 2881


The Efficacy of Imiquimod on Dysplastic Lesions of the Oral Mucosa: An Experimental Model. V. GKOULIONI, A. ELEFTHERIADOU, I. YIOTAKIS, E. FEREKIDOU, A. CHRISOVERGIS, A.CH. L, D. KANDILOROS (Athens; Crete, Greece) ........................................................................ 2891

Estrogen Receptors α and β Immunohistochemical Expression: Clinicopathological Correlations in Pituitary Adenomas. B. MANORANJAN, F. SALEHI, B.W. SCHEITHAUER, F. ROTONDO, K. KOVACS, M.D. CUSIMANO (Toronto, ON, Canada; Rochester, MN, USA) ................................................................. 2897

Clinical Studies

Docetaxel Second-line Therapy in Patients with Advanced Pancreatic Cancer: A Retrospective Study. M.W. SAIF, K. SYRIGOS, R. PENNEY, K. KALEY (New Haven, CT, USA; Athens, Greece) ......................................................... 2905


Zinc-α2-glycoprotein: A New Biomarker of Breast Cancer? V. DUBOIS, L. DELORT, F. MISHELLANY, T. JARDE, H. BILLARD, C. LEQUEUX, O. DAMOUR, F. PENAUSET-LLORCA, M.P. VASSON, F. CALDEFIE-CHEZET (Clermont-Ferrand; Lyon; Region Lyon Auvergne Rhone-Alpes, France) ......................................................... 2919

Role of Pregabalin in Treatment of Oxaliplatin-induced Sensory Neuropathy. M.W. SAIF, K. SYRIGOS, K. KALEY, I. ISUFI (New Haven, CT, USA; Athens, Greece) ......................................................... 2927

Effects of the Src Inhibitor Saracatinib (AZD0530) on Renal Function in Healthy Subjects. R.N. DALTON, R. CHETTY, M. STUART, R.B. IACONA, A. SWAISLAND (London; Cheshire, UK) ......................................................... 2935

Short Review: Validation of Blood Testing for K-ras Mutations in Colorectal and Pancreatic Cancer. M. ROGOSNITZKY, R. DANKS (Telz Stone, Israel; Sleep, UK) ......................................................... 2943

A ‘Hot’ Leg: A Rare Case of Isolated Long Bone Metastases from Cervical Cancer. A. DEWDNEY, U. SELVARAJAH (Romford, UK) ......................................................... 2949

Soluble Carbonic Anhydrase IX Is Not an Independent Prognostic Factor in Human Renal Cell Carcinoma. K. PAPWORTH, J. SANDLUND, K. GRANKVIST, B. LJUNGBERG, T. RASMUSON (Umeå; Stockholm, Sweden) ......................................................... 2953

Contents continued on the preceding page
PTHrP Regulates Angiogenesis and Bone Resorption via VEGF Expression. S. ISOWA, T. SHIMO, S. IBARAGI, N. KURIO, T. OKUI, K. MATSUBARA, N.M.M. HASSAN, K. KISHIMOTO, A. SASAKI (Okayama; Hiroshima, Japan) ................................................................. 2755
IL-8 and IL-6 Bystander Signalling in Human Glioblastoma Cells Exposed to Gamma Radiation. F. PASI, A. FACOETTI, R. NANO (Pavia, Italy) .................................................................................................................................................. 2769
Melphalan Modulates the Expression of E7-Specific Biomarkers in E7-Tg Mice. E.J. KIM, H. KIM, S. LEE, J.W. KANG, D.H. LEE, H.S. CHOI, J.M. KIM, Y. YANG, Y.Y. SHEEN, S.N. PARK, D.Y. YOON (Seoul; Daejeon; Soolmyung, Korea) .......................................................................................................................... 2773
Cell-free Circulating DNA: Diagnostic Value in Patients with Renal Cell Cancer. S. HAUSER, T. ZAHALKA, J. ELLINGER, G. FECHNER, C. DOBO, T.S. GOMES, D.A. RIBERIO, C.T.F. OSHIMA (Bonn; Munich, Germany) .......................................................................................................................... 2785
Role of Caspases and CD95/Fas in the Apoptotic Effects of a Nucleotide Analog PMEG in CCRF-CEM Cells. H. MERTLÍKOVÁ-KAISEROVÁ, I. VOTRUBA, M. MATOUŠOVÁ, A. HOLÝ, M. HÁJEK (Prague, Czech Republic) .................................................................................................................. 2791
Analysis of Chemotherapeutic Response Heterogeneity and Drug Clustering Based on Mechanism of Action Using an In Vitro Assay. S.D. RICE, J.M. HEINZMAN, S.L. BROWER, P.R. ERVIN, N. SONG, K. SHEN, D. WANG (Pittsburgh, PA 15203, USA) ................................................................. 2805
Hypoxia and Activated VEGF/Receptor Pathway in Multiple Myeloma. A. GIATROMANOLAKI, M. BAI, D. MARGARITIS, K.L. BOURANTAS, M.I. KOUKOURAKIS, E. SIVRIDIS, K.C. GATTER (Alexandroupolis; Ioannina, Greece; Oxford, UK) .......................................................................................................................... 2831
Immunohistochemical Analysis for Expression of Calpain 1, Calpain 2 and Calpastatin in Endometrial Cancer. D. SALEHN, I. FROMBERG, C. HAUHG, B. DOHMEN, T. GEORG, R.M. BOHLE, D. BAUERSCHLAG, N. MAASS, M. FRIEDRICH (Krefeld; Kaiserslautern; Homburg/Saar; Aachen, Germany) .......................................................................................................................... 2837
Expression of Ki-67 Antigen and Caspase-3 Protein in Benign Lesions and Esophageal Carcinoma. M. FERREIRA BELLINI, P.M. CURY, A.E. SILVA (São José do Rio Preto, SP, Brazil) ................................................................. 2845
Carbonyl Cyanide P-(Trifluoromethoxy) Phenylhydrozone Induces Caspase-independent Apoptosis in As4.1 Juxtaglomerular Cells. Y.H. HAN, Y.M. YANG, W.H. PARK (JeonJu, Republic of Korea) .......................................................................................................................... 2863